Trial Profile
A Phase II Study of Capecitabine, Carboplatin, and Bevacizumab for Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Carboplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 26 Aug 2019 Status changed from active, no longer recruiting to completed.
- 03 Feb 2012 Planned end date changed from 1 Apr 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 13 May 2009 Actual initiation date (1 Feb 2009) added as reported by ClinicalTrials.gov.